" /> Inebilizumab - CISMeF





Preferred Label : Inebilizumab;

NCIt definition : A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.;

UNII : 74T7185BMM;

CAS number : 1299440-37-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1299440-37-1 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : MEDI-551;

Details


You can consult :


Nous contacter.
10/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.